Structure of Stigmasterol
CAS No.: 83-48-7
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Stigmasterol is among the most abundant of plant sterols used as a food additive, with potential effect on lowering the levels of LDL cholesterol.
Synonyms: Stigmasterin; 5,22-Cholestadien-24-beta-ethyl-3-beta-ol
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 83-48-7 |
Formula : | C29H48O |
M.W : | 412.69 |
SMILES Code : | CC[C@](C(C)C)([H])/C([H])=C([H])/[C@@]([C@@]1([H])CC[C@@]2([H])[C@]([C@]3([H])CC[C@]12C)([H])CC=C4C[C@](O)([H])CC[C@@]43C)([H])C |
Synonyms : |
Stigmasterin; 5,22-Cholestadien-24-beta-ethyl-3-beta-ol
|
MDL No. : | MFCD00003630 |
InChI Key : | HCXVJBMSMIARIN-PHZDYDNGSA-N |
Pubchem ID : | 5280794 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
In Vitro:
Concentration | Treated Time | Description | References |
B16F10 cells | 0.5-50 µg/mL | 1 hour | To evaluate the inhibitory effect of STIG on H2O2-induced ROS levels. Results showed STIG significantly reduced H2O2-induced ROS levels. | Antioxidants (Basel). 2024 Mar 21;13(3):380 |
LS174T human colon cancer cells | 200 mM | 16 hours | Evaluate the activity of stigmasterol as an LXR agonist in human intestinal cells, results showed stigmasterol could induce the expression of LXR target gene ABCA1. | J Nutr Biochem. 2020 Feb;76:108263 |
L6 cells | 40 μg/mL | 20 minutes | Evaluate the effect of stigmasterol on GLUT4 translocation, results showed that stigmasterol treatment increased fluorescence intensity on L6 cell membranes, indicating enhanced GLUT4 translocation activity. | Food Nutr Res. 2017 Aug 23;61(1):1364117 |
U87 GBM cells | 10, 20, 40, 80, 120, 160, 200, 240 µM | 24 and 48 hours | Stigmasterol suppressed the proliferation of GBM cells in a dose- and time-dependent manner. | Mol Med Rep. 2024 Dec;30(6):227 |
B16F10 cells | 20 µg/mL | 24 hours | To evaluate the effect of STIG on PD-L1 expression. Results showed STIG significantly reduced IFN-γ-induced PD-L1 mRNA and protein levels. | Antioxidants (Basel). 2024 Mar 21;13(3):380 |
L6 cells | 10, 20, 40 μg/mL | 24 hours | Detect the effect of stigmasterol on glucose uptake, results showed that stigmasterol increased glucose uptake in a concentration-dependent manner. | Food Nutr Res. 2017 Aug 23;61(1):1364117 |
RAW264.7 cells | 15 µM | 24 hours | To investigate the effect of stigmasterol-treated LPS-induced Schwann cell-conditioned medium on the proliferation and migration of RAW264.7 cells. Results showed that L-S-CM significantly inhibited the proliferation and migration of RAW264.7 cells. | CNS Neurosci Ther. 2024 Apr;30(4):e14657 |
RSC96 cells | 15 µM | 24 hours | To investigate the effect of stigmasterol on IL-34 secretion in LPS-induced RSC96 cells. Results showed that stigmasterol significantly reduced the secretion of IL-34 in LPS-induced RSC96 cells. | CNS Neurosci Ther. 2024 Apr;30(4):e14657 |
OV90 cells | 0, 5, 10, 20 μg/mL | 24 hours | Induced apoptosis, activated caspase-3 and caspase-9 | Pharmaceutics. 2020 May 28;12(6):488 |
ES2 cells | 0, 5, 10, 20 μg/mL | 24 hours | Induced apoptosis, activated caspase-3 and caspase-9 | Pharmaceutics. 2020 May 28;12(6):488 |
Ishikawa cells | 10 μg/ml | 24 hours | Stigmasterol enhances the sensitivity of endometrial cancer cells to cisplatin by suppressing Nrf2 expression | Antioxidants (Basel). 2022 Jan 20;11(2):199 |
Ishikawa cells | 10 μg/ml | 24 hours | Stigmasterol enhances the sensitivity of endometrial cancer cells to cisplatin by suppressing Nrf2 expression | Cancer Cell Int. 2020 Oct 6;20:480 |
U87 GBM cells | 240 µM | 24 hours | Stigmasterol significantly reduced free fatty acid and total cholesterol levels in U87 GBM cells. | Mol Med Rep. 2024 Dec;30(6):227 |
U87 GBM cells | 240 µM | 24 hours | Stigmasterol significantly inhibited vasculogenic mimicry formation in U87 GBM cells. | Mol Med Rep. 2024 Dec;30(6):227 |
U87 GBM cells | 240 µM | 24 hours | Stigmasterol significantly inhibited the migration ability of U87 GBM cells. | Mol Med Rep. 2024 Dec;30(6):227 |
U87 GBM cells | 240 µM | 24 hours | Stigmasterol significantly reduced the number of invasive U87 GBM cells. | Mol Med Rep. 2024 Dec;30(6):227 |
U87 GBM cells | 240 µM | 24 hours | Stigmasterol significantly increased the proportion of apoptotic U87 GBM cells. | Mol Med Rep. 2024 Dec;30(6):227 |
4T1 isolated breast cancer stem-like cells | 0, 1, 5, 10 µM | 24 hours | Inhibits spheroid formation ability, cell viability, and migration ability, promotes cell apoptosis | J Cancer. 2025 Feb 3;16(5):1618-1630 |
SUM159 isolated breast cancer stem-like cells | 0, 1, 5, 10 µM | 24 hours | Inhibits spheroid formation ability, cell viability, and migration ability, promotes cell apoptosis | J Cancer. 2025 Feb 3;16(5):1618-1630 |
Mouse chondrogenic cells (ATDC5 cells) | 5, 10, 20, 40 μg/mL | 24 hours | To detect the effect of stigmasterol on the viability of ATDC5 cells, the results showed that 0-20 μg/ml STM had no significant effect on cell viability, while 40 μg/ml STM showed inhibitory effects. | Bioengineered. 2021 Dec;12(2):9332-9340 |
Liver epithelial cells THLE-2 | 10, 50, 100 µg/mL | 48 hours | Assessed cytotoxicity and metabolic activity, showing DP3SSt inhibited cell proliferation and viability at 50 and 100 µg/mL, while other derivatives had no significant effect | Sci Rep. 2023 Dec 4;13(1):21375 |
Colon mucosa cells CCD 841CoN | 10, 50, 100 µg/mL | 48 hours | Assessed cytotoxicity and metabolic activity, showing no toxicity from unheated and heated Stigmasterol derivatives, with DO3SSt promoting cell proliferation at specific concentrations | Sci Rep. 2023 Dec 4;13(1):21375 |
Small intestine epithelial cells FHS 74Int | 10, 50, 100 µg/mL | 48 hours | Assessed cytotoxicity and metabolic activity, showing no toxicity from unheated and heated Stigmasterol derivatives, with DO3SSt promoting cell proliferation at specific concentrations | Sci Rep. 2023 Dec 4;13(1):21375 |
MGC-803 | 10, 20 µM | 48 hours | To evaluate the effect of Stigmasterol on cell proliferation, results showed that Stigmasterol significantly inhibited cell viability in a time- and dose-dependent manner in MGC-803 cells. | Front Oncol. 2021 Feb 23;11:629008 |
SGC-7901 | 10, 20 µM | 48 hours | To evaluate the effect of Stigmasterol on cell proliferation, results showed that Stigmasterol significantly inhibited cell viability in a time- and dose-dependent manner in SGC-7901 cells. | Front Oncol. 2021 Feb 23;11:629008 |
OV90 cells | 0, 5, 10, 20 μg/mL | 48 hours | Increased mitochondrial depolarization, ROS production, and calcium overload | Pharmaceutics. 2020 May 28;12(6):488 |
ES2 cells | 0, 5, 10, 20 μg/mL | 48 hours | Increased mitochondrial depolarization, ROS production, and calcium overload | Pharmaceutics. 2020 May 28;12(6):488 |
Human normal colon mucosa CCD 841 CoN cells | 2.5, 5, 10, 20, 40 μg/mL | 48 hours | To assess the effect of stigmasterol on DNA synthesis. Results showed that non-heated stigmasterol at 5 μg/mL significantly inhibited DNA synthesis, and at 40 μg/mL decreased DNA synthesis by 61%. Heated stigmasterol at 20 and 40 μg/mL reduced DNA synthesis by 31% and 39%, respectively. | Sci Rep. 2023 May 1;13(1):7093 |
Human normal colon mucosa CCD 841 CoN cells | 1.25, 2.5, 5, 10, 20, 40 μg/mL | 48 hours | To evaluate the cytotoxicity of stigmasterol and its esters on colon mucosa cells. Results showed that non-heated stigmasterol at 40 μg/mL reduced viable cell number by approximately 80%, while heated stigmasterol showed lower cytotoxicity at the same concentration. | Sci Rep. 2023 May 1;13(1):7093 |
RAW 264.7 cells | 0, 1, 2.5, 5, 10 µM | 48 hours | To evaluate the effect of STG on the viability of RAW 264.7 cells. Results showed no significant change in cytotoxicity within concentrations ranging from 0 to 10 μM, but cellular viability decreased at 20 μM. | Front Pharmacol. 2024 Dec 16;15:1527494 |
BEAS-2B cells | 10 μg/mL and 20 μg/mL | 48 hours | To verify the anti-inflammatory and antioxidant stress effects of stigmasterol and to reduce NK1-R expression in IL-13-induced BEAS-2B cells. | Pharm Biol. 2023 Dec;61(1):449-458 |
RAW 264.7 cells | 5, 10 µM | 6-7 days | To evaluate the effect of STG on osteoclast-specific gene expression. Results showed that STG significantly downregulated the expression of Acp5, NFATc1, c-Fos, and CTSK genes. | Front Pharmacol. 2024 Dec 16;15:1527494 |
RAW 264.7 cells | 0, 1, 2.5, 5, 10 µM | 6-7 days | To assess the effect of STG on RANKL-induced osteoclast differentiation. Results showed that STG significantly inhibited osteoclast formation in a dose-dependent manner. | Front Pharmacol. 2024 Dec 16;15:1527494 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
C57BL/6J mice | High cholesterol diet model | Oral | 0.3% (w/w) | 4 consecutive days | Assess the effect of stigmasterol on cholesterol balance and secretion, results showed stigmasterol promoted intestinal cholesterol secretion but did not depend on LXR activation pathway. | J Nutr Biochem. 2020 Feb;76:108263 |
C57BL/6J male mice | DSS-induced colitis model | Oral via diet | 0.4% diet supplementation | Fed for 1 week followed by 1.5% DSS in drinking water for 5 days | To evaluate the protective effects of Stigmasterol against DSS-induced colitis. Results showed that Stigmasterol significantly inhibited colon shortening, reduced fecal hemoglobin content, decreased colonic inflammation score, and downregulated the expression of NF-κB, COX-2, and CSF-1. | Food Funct. 2017 Nov 15;8(11):4179-4186 |
Mice | High-fat western-style diet-induced NAFLD model | Diet | 0.4% in diet | 17 weeks | To investigate the effects of stigmasterol and β-sitosterol on high-fat western-style diet-induced NAFLD. Results showed that stigmasterol significantly ameliorated HFWD-induced fatty liver and metabolic abnormalities, including elevated levels of hepatic total lipids, triacylglycerols, cholesterol and liver histopathology. | Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Oct;1863(10):1274-1284 |
BALB/C nude mice | Breast cancer stem cell transplantation model | Mammary fat pad injection | 10 mg/kg | Once a week for 1.5 months | Significantly inhibits tumor formation ability and reverses its inhibitory effect by suppressing JAK3 expression | J Cancer. 2025 Feb 3;16(5):1618-1630 |
C57BL/6J mice | OVA-induced asthma mouse model | Intraperitoneal injection | 100 mg/kg | 7 consecutive days | To evaluate the anti-inflammatory and antioxidant stress effects of stigmasterol in OVA-induced asthma mice and to verify the role of NK1-R as a potential target. | Pharm Biol. 2023 Dec;61(1):449-458 |
Wistar rats | Cerebral ischemia/reperfusion injury model | Oral | 20, 40, 80 mg/kg | 1 week | Stigmasterol alleviates cerebral ischemia/reperfusion injury by attenuating inflammation and improving antioxidant defenses in rats. | Biosci Rep. 2020 Apr 30;40(4):BSR20192133 |
C57/BL6 male mice | OVA-induced asthma mouse model | Oral | 5 mg/kg, 10 mg/kg, 20 mg/kg | Every 2 days from day 21 to day 43 | Stigmasterol alleviated OVA-induced airway inflammation, reduced the number of inflammatory cells in BALF, decreased levels of IL-1β, IL-5, IL-6, and IL-13, and inhibited the TGF-β1/Smad2 and IL-17A signaling pathways | Aging (Albany NY). 2024 Apr 4;16(7):6478-6487 |
C57BL/6J female mice | Ovariectomy (OVX) osteoporosis model | Oral | 5, 10 mg/kg | Administered every other day for 8 weeks | To evaluate the protective effect of STG against OVX-induced osteoporosis. Results showed that STG significantly reduced the number and surface area of osteoclasts and effectively prevented bone loss. | Front Pharmacol. 2024 Dec 16;15:1527494 |
KK-Ay mice | High-fat diet-induced type 2 diabetes model | Oral | 50 mg/kg/day, 100 mg/kg/day | Once daily for 4 weeks | Evaluate the hypoglycemic effect of stigmasterol in type 2 diabetic mice, results showed that stigmasterol significantly reduced fasting blood glucose levels and improved insulin resistance and oral glucose tolerance. | Food Nutr Res. 2017 Aug 23;61(1):1364117 |
Sprague-Dawley rats | Chronic constriction injury (CCI) model | Oral gavage | 80 mg/kg | Once daily for 21 days | To investigate the effect of stigmasterol on neuropathic pain in CCI rats. Results showed that stigmasterol significantly reduced thermal and cold hyperalgesia in CCI rats and decreased the levels of IL-1β, IL-6, TNF-α, CCL2, SP, and PGE2 in serum. | CNS Neurosci Ther. 2024 Apr;30(4):e14657 |
Sprague-Dawley (SD) rats | High-fat diet (HFD)-induced hyperlipidemia and hepatic steatosis model | Intragastric administration | Low-dose group: 100 mg/kg; High-dose group: 200 mg/kg | Daily administration for 4 weeks | ST treatment significantly alleviated HFD-induced hyperlipidemia and hepatic fat deposition, mainly dependent on the bile acid metabolic pathway. ST also improved intestinal barrier function and gut microbiota in HFD-fed rats, resulting in changes in bile acid metabolism. | NPJ Sci Food. 2022 Aug 27;6(1):38 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT00698256 | Hypercholesterolemia | Not Applicable | Completed | - | Finland ... More >> University of kuopio Kuopio, Finland, 70211 Less << |
NCT02702947 | BPH | Phase 4 | Completed | - | India ... More >> Department of Urology, King George's Medical University, Lucknow, UP, India Lucknow, Uttar Pradesh, India, 226003 Less << |
NCT00718796 | Cardiovascular Disease | Phase 3 | Completed | - | Canada, Ontario ... More >> Canadian College of Naturopathic Medicine Toronto, Ontario, Canada, M2K 1E2 Less << |
NCT01010841 | Metabolic Syndrome ... More >> Overweight Obesity Hypercholesterolemia Less << | Not Applicable | Completed | - | United States, Florida ... More >> Mark McIntosh MD Jacksonville, Florida, United States, 32209 Less << |
NCT03739242 | Hypercholesterolemia | Not Applicable | Completed | - | Italy ... More >> Policlinico S.Orsola - Malpighi Medicina Interna Borghi Bologna, Italy, 40138 Less << |
NCT02221973 | Primary Dyslipidemia | Not Applicable | Completed | - | China ... More >> Anzhen Hospital, Capital University of Medical Sciences Beijing, China Chao Yang 2nd Hospital Beijing, China Chui Yang Liu Hospital Beijing, China Less << |
NCT01954472 | Cardiovascular Diseases ... More >> Type 2 Diabetes Hypercholesterolemia Less << | Not Applicable | Withdrawn(This study was combi... More >>ned with another CIHR funded study (NCT02078635). Both studies involve the same dietary portfolio and the same study population.) Less << | - | Canada, British Columbia ... More >> Healthy Heart Lipid Clinic, St. Paul's Hospital Vancouver, British Columbia, Canada, V6Z 1Y6 Canada, Manitoba Richardson Center for Functional Foods and Nutraceuticals and the St. Boniface Hospital Cardiovascular Center, University of Manitoba Winnipeg, Manitoba, Canada, R3T 6C5 Canada, Ontario Risk Factor Modification Centre, St. Michael's Hospital Toronto, Ontario, Canada, M5C 2T2 Canada, Quebec Institute of Nutraceuticals and Functional Foods and the Quebec Heart and Lung Institute, Laval University Quebec City, Quebec, Canada, G1V 4G2 Less << |
NCT02481466 | Cardiovascular Diseases ... More >> Hypercholesterolemia Type 2 Diabetes Metabolic Syndrome Less << | Not Applicable | Recruiting | December 2022 | Canada, British Columbia ... More >> Healthy Heart Lipid Clinic, St. Paul's Hospital Recruiting Vancouver, British Columbia, Canada, V6Z 1Y6 Principal Investigator: Jiri Frohlich, MD Canada, Manitoba Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba Not yet recruiting Winnipeg, Manitoba, Canada, R3T 6C5 Contact: Peter Jones, PhD Principal Investigator: Peter Jones, PhD Canada, Ontario Risk Factor Modification Centre, St. Michael's Hospital Recruiting Toronto, Ontario, Canada, M5C 2T2 Contact: David J Jenkins, MD PhD 416-867-7475 David.jenkins@utoronto.ca Contact: Dorothea A Faulkner, PhD 416-360-4000 ext 48175 FaulknerD@smh.ca Principal Investigator: David J Jenkins, MD PhD Sub-Investigator: Cyril Kendall, PhD Sub-Investigator: Robert Josse, MD Sub-Investigator: Lawrence Leiter, MD Sub-Investigator: John Sievenpiper, MD PhD Sub-Investigator: Anish Kirpalani, MD Canada, Quebec Institute of Nutraceuticals and Functional Foods, Laval University Recruiting Quebec City, Quebec, Canada, G1V 4G2 Contact: Benoit Lamarche, PhD Principal Investigator: Benoit Lamarche, PhD Less << |
NCT00345722 | Hyperlipidemia ... More >> Cardiovascular Diseases Hypercholesterolemia Less << | Phase 2 | Completed | - | Canada, Ontario ... More >> Clinical Nutrition & Risk Factor Modification Centre, St. Michael's Hospital Health Centre Toronto, Ontario, Canada, M5C 2T2 Less << |
NCT03681392 | Prostatism Er... More >>ectile Dysfunction Less << | Not Applicable | Not yet recruiting | March 2020 | - |
NCT01031485 | Stage 1 Hypertension | Phase 3 | Completed | - | Finland ... More >> Valio Ltd Helsinki, Uusimaa, Finland, 00370 Less << |
NCT03728244 | Graft Pain Gi... More >>ngival Recession Less << | Phase 1 Phase 2 | Not yet recruiting | August 2020 | - |
NCT00249938 | Hyperlipidemia ... More >> Dyslipidemia Less << | Phase 4 | Completed | - | United States, Colorado ... More >> University of Colorado at Denver and Health Sciences Center Denver, Colorado, United States, 80262 Less << |
NCT03534414 | - | Active, not recruiting | October 1, 2018 | Canada, Ontario ... More >> The Toronto 3D (Diet, Digestive tract and Disease) Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Micheal's Hospital Toronto, Ontario, Canada, M5C 2T2 Less << | |
NCT01584206 | Sitosterolemia | Not Applicable | Unknown | December 2016 | Canada, Manitoba ... More >> Richardson Centre for Functional Foods and Nutraceuticals Winnipeg, Manitoba, Canada, R3T 2N2 Less << |
NCT00438425 | Hyperlipidemia ... More >> Cardiovascular Disease Less << | Not Applicable | Completed | - | Canada, British Columbia ... More >> Healthy Heart Program, St. Paul's Hospital Vancouver, British Columbia, Canada, V6Z 1Y6 Canada, Manitoba Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba Winnipeg, Manitoba, Canada, R3T 6C5 Canada, Ontario Sunnybrook Health Sciences Centre Toronto, Ontario, Canada, M4N 3M5 St. Michael's Hospital Toronto, Ontario, Canada, M5C 2T2 Canada, Quebec Institute on Nutraceuticals and Functional Foods and the Lipid Research Center, Laval University Hospital Research Center Quebec City, Quebec, Canada, G1V 4G2 Less << |
NCT00793364 | Hypercholesterolemia | Phase 4 | Completed | - | Greece ... More >> Aristotelian University, Hippocration Hospital Thessaloniki, Greece, 55132 Less << |
NCT01948648 | Sitosterolemia | Not Applicable | Recruiting | December 31, 2019 | Canada, Manitoba ... More >> Richardson Center for Functional Foods and Nutraceuticals Recruiting Winnipeg, Manitoba, Canada Contact: Semone B Myrie, PhD 204-272-1555 myrie@cc.umanitoba.ca Contact: Peter J Jones, PhD 204-474-8883 Peter.Jones@umanitoba.ca Sub-Investigator: Semone B Myrie, PhD Principal Investigator: Peter J Jones, PhD Sub-Investigator: David Mymim, PhD Sub-Investigator: Taback Shayne, PHD Less << |
NCT01084226 | Hypercholesterol | Phase 2 | Completed | - | Finland ... More >> Folkhälsan Research Center Helsinki, Finland, 00290 Less << |
NCT02078635 | Cardiovascular Diseases ... More >> Hypercholesterolemia Diabetes Metabolic Syndrome Obesity Less << | Not Applicable | Withdrawn(Study was amalgamate... More >>d with another study to include exercise as another intervention.) Less << | - | Canada, British Columbia ... More >> Healthy Heart Lipid Clinic, St. Paul's Hospital Vancouver, British Columbia, Canada, V6Z 1Y6 Canada, Manitoba Richardson Center for Functional Foods and Nutraceuticals and the St. Boniface Hospital Cardiovascular Center, University of Manitoba Winnipeg, Manitoba, Canada, R3T 6C5 Canada, Ontario Risk Factor Modification Centre, St. Michael's Hospital Toronto, Ontario, Canada, M5C 2T2 Canada, Quebec Institute of Nutraceuticals and Functional Foods and the Quebec Heart and Lung Institute, Laval University Quebec City, Quebec, Canada, G1V 4G2 Less << |
NCT01629238 | - | Completed | - | France ... More >> BKL Consultant Boulogne-Billancourt, France, 92100 Less << | |
NCT00924391 | Coronary Heart Disease | Phase 2 | Completed | - | Canada, Manitoba ... More >> Richardson Centre for Functional Foods and Nutraceuticals Winnipeg, Manitoba, Canada, R3T 2N2 Less << |
NCT00923403 | Hypercholesterolemia | Phase 1 Phase 2 | Completed | - | Canada, Manitoba ... More >> Richardson Centre for Functional Foods and Nutraceuticals Winnipeg, Manitoba, Canada, R3T 6C5 Less << |
NCT00438893 | Hyperlipidemia ... More >> Cardiovascular Diseases Hypercholesterolemia Less << | Not Applicable | Completed | - | Canada, Ontario ... More >> Clinical Nutrition & Risk Factor Modification Centre, St. Michael's Hospital Health Centre Toronto, Ontario, Canada, M5C 2T2 Less << |
NCT00846937 | Ileostoma | Not Applicable | Completed | - | Finland ... More >> University of Helsinki, Department of Medicine Helsinki, Finland, 00029 Less << |
NCT00940849 | Gastric Emptying | Not Applicable | Completed | - | Netherlands ... More >> Maastricht University Medical Center Maastricht, Limburg, Netherlands, 6200 Less << |
NCT00802516 | Hypercholesterolemia | Not Applicable | Completed | - | Netherlands ... More >> Maastricht University Maastricht, Netherlands, 6229ER Less << |
NCT03469518 | Hypercholesterolemia ... More >> Osteoporosis Postmenopausal Disorder Less << | Not Applicable | Active, not recruiting | December 2018 | - |
NCT03065491 | Hypercholesterolemia | Not Applicable | Completed | - | Italy ... More >> S. Orsola-Malpighi University Hospital Bologna, BO, Italy, 40138 Less << |
NCT00441857 | Hypercholesterolemia | Phase 4 | Completed | - | Finland ... More >> Oy Foodfiles Ltd Kuopio, Finland, 70210 Less << |
NCT01521169 | Normal and Mild Hypercholester... More >>olemic Subjects Less << | Not Applicable | Completed | - | Japan ... More >> Senrichuo Ekimae Clinic - Senri Life Science Center 13F Osaka, Japan, 560-0082 Less << |
NCT03312816 | Healthy | Not Applicable | Completed | - | Germany ... More >> Charité Research Organisation GmbH Berlin, Germany, 10117 Less << |
NCT02732223 | Cardiovascular Diseases | Not Applicable | Completed | - | - |
NCT01932840 | - | Completed | - | Canada, Ontario ... More >> University of Guelph Guelph, Ontario, Canada Less << | |
NCT01600820 | Hypercholesterolemia | Not Applicable | Completed | - | Spain ... More >> Hospital de Sant Joan Reus, Spain, 43201 Less << |
NCT00422266 | Dyslipidemia | Phase 3 | Completed | - | India ... More >> National Thermal Power Corporation Delhi, Badarpur, India Less << |
NCT00485095 | High Blood Cholesterol Level | Phase 4 | Completed | - | Norway ... More >> Lipidklinikken, Rikshospitalet Radiumhospitalet HF Oslo, Norway Rikshospitalet Radiumhospitalet HF, Oslo, Norway Oslo, Norway Less << |
NCT01882517 | Hypercholesterolemia ... More >> Hyperlipidemias Dyslipidemias Less << | Not Applicable | Completed | - | Turkey ... More >> Hacettepe University Ankara, Turkey Less << |
NCT01716390 | Hypercholesterolemia | Not Applicable | Completed | - | Sweden ... More >> Good Food Practice Uppsala, Sweden Less << |
NCT00222950 | - | Unknown | - | Germany ... More >> University of the Saarland Recruiting Homburg, Saarland, Germany, 66421 Contact: Oliver Weingartner, M.D. 0049-(0)68411623372 oweingartner@aol.com Contact: Ulrich Laufs, M.D. 0049-(0)68411623372 ulrich@laufs.com Sub-Investigator: Oliver Weingartner, M.D. Less << | |
NCT01825668 | Hypercholesterolemia ... More >> CVD Less << | Not Applicable | Unknown | June 2016 | Canada, Manitoba ... More >> Richardson Centre for Functional Foods and Nutraceuticals Winnipeg, Manitoba, Canada, R3T 2N2 Less << |
NCT01340287 | Hypercholesterolemia | Not Applicable | Completed | - | United States, Florida ... More >> Renstar Medical Research Ocala, Florida, United States Less << |
NCT01478789 | Hypercholesterolemia | Not Applicable | Completed | - | Canada, Manitoba ... More >> Richarson Centre for Funtional Foods and Nutraceuticals Winnipeg, Manitoba, Canada, R3T 2N2 Less << |
NCT01461798 | Risk Reduction Behavior | Not Applicable | Unknown | March 2012 | - |
NCT00897975 | Hyperlipidemia | Phase 2 Phase 3 | Completed | - | United States, Pennsylvania ... More >> Abington Memorial Hospital Abington, Pennsylvania, United States Chestnut Hill Hospital Philadelphia, Pennsylvania, United States, 19118 Less << |
NCT02628990 | Hypercholesterolemia ... More >> Hyperlipidemias Dyslipidemias Less << | Not Applicable | Completed | - | - |
NCT01629888 | Healthy Mild ... More >>Hypercholesterolemia Less << | Not Applicable | Completed | - | Japan ... More >> Senri Chuo Ekimae Clinic Osaka, Japan, 560-0082 Less << |
NCT00145717 | Hypercholesterolemia ... More >> Cardiovascular Diseases Less << | Phase 3 | Completed | - | China ... More >> Peking University Health Science Centre Beijing, China, 100083 Less << |
NCT02947594 | - | Completed | - | - | |
NCT01574469 | Mildly Hypercholesterolemic Su... More >>bjects Less << | Not Applicable | Completed | - | France ... More >> Hôpital Pitié-Salpêtrière Paris, France, 75013 Less << |
NCT02475018 | Hypercholesterolemia | Not Applicable | Completed | - | China, Beijing ... More >> BaiZhiFang Community Health Service Centre Beijing, Beijing, China, 100053 Less << |
NCT01313988 | Healthy Mildl... More >>y Elevated Cholesterol Levels Less << | Not Applicable | Completed | - | Sweden ... More >> KPL Good Food Practice AB Uppsala, Sweden, S-751 83 Less << |
NCT00863265 | Hypercholesterolemia ... More >> Coronary Heart Disease Less << | Early Phase 1 | Completed | - | United States, Utah ... More >> Center for Advance Nutrition at Utah State University Logan, Utah, United States, 84322-4715 Less << |
NCT02779673 | LDL-cholesterol Level 130-159m... More >>g/dL Less << | Not Applicable | Completed | - | - |
NCT02221297 | Hypercholesterolemia ... More >> Hyperlipidemias Dyslipidemias Less << | Not Applicable | Completed | - | - |
NCT01574482 | Mildly Hypercholesterolemic Su... More >>bjects Less << | Not Applicable | Completed | - | Italy ... More >> Ospedale Silvestrini Perugia, Italy, 06129 Less << |
NCT00863265 | - | Completed | - | - | |
NCT01571869 | Mildly Hypercholesterolemic Su... More >>bjects Less << | Not Applicable | Completed | - | Canada, Quebec ... More >> McGill University Ste-anne-de-bellevue, Quebec, Canada, H9X 3V9 Less << |
NCT02316808 | Dyslipidemias ... More >> Hypercholesterolemia Hyperlipidemias Less << | Not Applicable | Completed | - | - |
NCT00153738 | Hypercholesteremia | Not Applicable | Completed | - | United States, Texas ... More >> The Cooper Institute Dallas, Texas, United States, 75230 Less << |
NCT01521156 | Mild Hypercholesterolemic Subj... More >>ects Less << | Not Applicable | Completed | - | Germany ... More >> Harrison Clinical Research Clinical Unit Munich, Germany, 80636 Less << |
NCT03705767 | - | Completed | - | - | |
NCT01571882 | Mildly Hypercholesterolemic Su... More >>bjects Less << | Not Applicable | Completed | - | United Kingdom ... More >> Guildford Clinical Pharmacology Unit Ltd. (Gcpl) Guildford, Surrey, United Kingdom, GU2 7YG Less << |
NCT02459314 | Hypercholesterolemia | Not Applicable | Completed | - | Thailand ... More >> Clinical trial Unit, Faculty of Medicine, Chiang Mai University Muang, ChiangMai, Thailand, 50200 Less << |
NCT02644109 | Dyslipidemias ... More >> Hypercholesterolemia Less << | Phase 4 | Completed | - | Chile ... More >> Instituto de Nutricion y Tecnologia de los Alimentos, Universidad de Chile Santiago, Región Metropolitana de Santiago, Chile Department of Nutrition, Diabetes and Metabolism. Pontificia Universidad Catolica de Chile Santiago, Chile Less << |
NCT01205308 | Type 1 Diabetes | Not Applicable | Completed | - | Finland ... More >> University of Eastern Finland Kuopio, Finland, FIN-70211 Less << |
NCT02765516 | Hypercholesterolemia ... More >> Cardiovascular Disease Less << | Not Applicable | Recruiting | December 2019 | Canada, Manitoba ... More >> Department of Human Nutritional sciences, University of Manitoba Recruiting Winnipeg, Manitoba, Canada, R3T2N2 Contact: James House, PhD 204-474-6837 james.house@umanitoba.ca Principal Investigator: James House, PhD Less << |
NCT03284918 | Hypercholesterolemia ... More >> Hyperlipidemias Dyslipidemias Less << | Not Applicable | Completed | - | - |
NCT00738933 | Hypercholesterolemia ... More >> Atherosclerosis Less << | Not Applicable | Unknown | December 2011 | Finland ... More >> Department of Medicine, Div. of Internal Medicine, Helsinki Univ. Central Hospital (HUCH) Recruiting Helsinki, Finland, 00029HUS Contact: Markku Nissinen, MD, PhD +358 9 4711 markku.nissinen@hus.fi Principal Investigator: Tatu A Miettinen, Professor Sub-Investigator: Markku J Nissinen, MD, PhD Less << |
NCT02644109 | - | Completed | - | - | |
NCT01715675 | Asthma Allerg... More >>y Less << | Not Applicable | Completed | - | Netherlands ... More >> Maastricht University Medical Centre Maastricht, Limburg, Netherlands, 6229ER Less << |
NCT00720720 | Hypercholesterolemia | Not Applicable | Terminated(Recruitment and org... More >>anizational difficulties) Less << | - | France ... More >> Hôpital cardio-vasculaire et pneumologique Louis Pradel Bron, France, 69677 Clinique d'Endocrinologie, Maladies Métaboliques et Nutrition Nantes, France, 44093 Groupe Hospitalier Pitié-Salpêtrière, Endocrinology and Metabolism Department Paris, France, 75013 Less << |
NCT00920894 | Elevated Blood Lipids | Not Applicable | Completed | - | Finland ... More >> Clinical Life Sciences Ltd Vuokatti, Finland, 88610 Less << |
NCT00441480 | - | Completed | - | - | |
NCT03723330 | Cardiovascular Diseases ... More >> Endothelial Dysfunction Metabolic Syndrome Diet Modification Less << | Not Applicable | Not yet recruiting | May 2020 | - |
NCT00441480 | Dyslipidemia | Phase 4 | Completed | - | Israel ... More >> Sheba medical center Tel-HaShomer, Israel, 52621 Less << |
NCT02603276 | Hypercholesterolemia | Not Applicable | Completed | - | Italy ... More >> S. Orsola-Malpighi University Hospital Bologna, Italy, 40038 Less << |
NCT00737919 | Atherosclerosis | Not Applicable | Completed | - | Finland ... More >> Department of Surgery, Div. of Vascular Surgery, Helsinki University Central Hospital Helsinki, Finland, 00029 Less << |
NCT02969720 | Metabolic Syndrome x | Phase 3 | Unknown | December 2017 | - |
NCT00860054 | Hypercholesterolemia ... More >> Coronary Heart Disease Less << | Not Applicable | Completed | - | United States, Louisiana ... More >> Pennington Biomedical Research Center Baton Rouge, Louisiana, United States, 70808 Less << |
NCT02728583 | Vascular Diseases ... More >> Hypercholesterolemia Less << | Not Applicable | Completed | - | Germany ... More >> Charite Research Organisation Berlin, Germany Less << |
NCT02278393 | Healthy Volunteers | Not Applicable | Completed | - | Japan ... More >> Yaesu Sakura-dori Clinic Tokyo, Japan, 103-0028 Less << |
NCT01712867 | Patients With Hypertriglycerid... More >>emia Less << | Not Applicable | Completed | - | Israel ... More >> Maccabi Healthcare Services Tel-Aviv, Israel Less << |
NCT01803178 | Vascular Diseases ... More >> Hypercholesterolemia Less << | Not Applicable | Completed | - | Germany ... More >> Charité Research Organisation Berlin, Germany Less << |
NCT00860509 | Hypercholesterolemia ... More >> Coronary Heart Disease Less << | Not Applicable | Completed | - | United States, Louisiana ... More >> Pennington Biomedical Research Center-Louisana State University System Baton Rouge, Louisiana, United States, 70808 Less << |
NCT02065024 | Hypercholesterolemia ... More >> Osteoporosis Less << | Phase 1 | Completed | - | Spain ... More >> Hospital Universitario Puerta de Hierro-Majadahonda Majadahonda (Madrid), Madrid, Spain, 28222 Less << |
NCT02268318 | Subjects With High LDL-Cholest... More >>erol Less << | Not Applicable | Completed | - | Japan ... More >> Yaesu Sakura-dori Clinic Tokyo, Japan, 103-0028 Less << |
NCT02758834 | - | Completed | - | - | |
NCT02881658 | Dyslipidemia | Not Applicable | Completed | - | Hong Kong ... More >> Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam Hong Kong, Hong Kong Less << |
NCT02881658 | - | Completed | - | - | |
NCT01574417 | Hypercholesterolemia | Not Applicable | Completed | - | Netherlands ... More >> Maastricht University Medical Centre Maastricht, Limburg, Netherlands Less << |
NCT01559428 | Normocholesterolemic | Not Applicable | Completed | - | Netherlands ... More >> Maastricht University Medical Centre Maastricht, Limburg, Netherlands, 6229 ER Less << |
NCT01406106 | Hypercholesterolemia | Not Applicable | Unknown | December 2012 | - |
NCT01315964 | Atherosclerosis | Not Applicable | Completed | - | Finland ... More >> Biomedicum Helsinki Helsinki, Finland, 00029 Less << |
NCT01102647 | Cardiovascular Disease | Phase 1 | Completed | - | Canada, Manitoba ... More >> University of Manitoba Winnipeg, Manitoba, Canada, R3T 2N2 Less << |
NCT02288585 | Vascular Diseases ... More >> Hypercholesterolemia Diabetes Mellitus Less << | Not Applicable | Completed | - | Australia ... More >> CSIRO Adelaide, Australia CSIRO, North Ryde Sydney, Australia Less << |
NCT01074723 | Postmenopausal Disorder | Phase 1 | Completed | - | Spain ... More >> Puerta de Hierro University Hospital Madrid, Spain, 28222 Less << |
NCT03627819 | Non-Alcoholic Fatty Liver Dise... More >>ase Less << | Not Applicable | Recruiting | December 2019 | Netherlands ... More >> Maastricht University Medical Centre Recruiting Maastricht, Limburg, Netherlands, 6229 ER Contact: Sabine Baumgartner, Dr. +31 (0)43 3881305 sabine.baumgartner@maastrichtuniversity.nl Less << |
NCT02089867 | Coronary Artery Disease | Phase 2 Phase 3 | Completed | - | Brazil ... More >> Jose Rocha Faria Neto Curitiba, Paraná, Brazil, 80215-901 Less << |
NCT02331043 | Dyslipidemias ... More >> Hypercholesterolemia Hyperlipidemias Less << | Not Applicable | Completed | - | Thailand ... More >> Mahidon University, Nutrition Institute, Center of Innovation and Reference on Food for Nutrition (CIRFON) Phutthamonthon, Nakhon Pathom, Thailand, 73170 Less << |
NCT01131832 | Hyperlipidemia | Phase 4 | Completed | - | United States, Maryland ... More >> USDA-ARS, Beltsville Human Nutrition Research Center Beltsville, Maryland, United States, 20705 Canada, Manitoba Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba Winnipeg, Manitoba, Canada, R3T 6C5 Less << |
NCT01875978 | Non-alcoholic Fatty Liver Dise... More >>ase Less << | Not Applicable | Completed | - | Taiwan ... More >> China Medical University Hospital Taichung, Taiwan Less << |
NCT01875978 | - | Completed | - | - | |
NCT02541201 | Dyslipidemia | Phase 2 | Completed | - | - |
NCT00928616 | Hyperlipidemia | Not Applicable | Unknown | June 2009 | Germany ... More >> Universitätsklinikum des Saarlandes, Klinik für Innere Medizin III Homburg, Saarland, Germany, 66421 Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.42mL 0.48mL 0.24mL |
12.12mL 2.42mL 1.21mL |
24.23mL 4.85mL 2.42mL |